Background and aim: The objective of this research was to determine whether invasively measured central pulse pressure (PP) in patients indicated for coronarography is associated with two common polymorphisms in the ACE2 region (rs4646156 and rs4646174). Methods: A total of 307 patients were enrolled in the study. The genotyping of both SNPs from peripheral blood samples was carried out using 5′exonuclease (Taqman®) chemistry on the ABI Prism® 7000 system (Applied Biosystems, Foster City, CA, USA). Results: In both polymorphisms, the associations with central PP were found to be highly significant when all five possible genotypes in the population had been compared (p = 0.0001). In men, there was a higher incidence of previous myocardial infarction in G0 genotype carriers of rs54646174 (OR ratio = 7; p = 0.005). The AA genotype of rs4646156 had a 7.81× higher risk of severe angina pectoris in women (OR = 7.81, p = 0.05). A significant difference in allelic frequency of ACE2rs4646174 was found between women with and without significant stenoses of the circumflex branch of the left coronary artery. Conclusion: More research into the role of ACE2 genetic variability in PP regulations is necessary for more detailed physiological and pathophysiological comprehension of PP regulation.
Introduction
The renin-angiotensin system (RAS) is thought to have evolved as a short-term defence mechanism against hypovolemic hypertension, typically arising from haemorrhage or dehydration, at a time when both of these constituted the principal threat to cardiovascular integrity and function as well as survival. 1 Recent evidence shows that the RAS is a crucial player in the atherosclerotic process. Since it was initially reported, it has been considered one of the main mechanisms involved. Vasoconstriction (mediated by angiotensin II) and salt and water retention (mainly due to aldosterone) are traditionally considered to be the pivotal proatherosclerotic activities. However, primary research and animal studies strongly support the hypothesis that angiotensin II acts as a proinflammatory mediator directly inducing atherosclerotic plaque development and heart remodelling. Furthermore, angiotensin II induces proatherosclerotic cytokine and chemokine secretion and increases endothelial dysfunction. Moreover, the pharmacological inhibition of the RAS significantly improves the prognosis of patients with cardiovascular diseases, even under normal baseline blood pressure. 2 However, in 2000, another enzyme operating in the RAS was identified 3 that led to substantial changes in the perception of RAS. Whereas angiotensin-converting enzyme 1 (ACE) converts angiotensin I to angiotensin II, which has eight amino acids, angiotensin-converting enzyme 2 (ACE2) converts angiotensin I to angiotensin (Ang)-1-9, which has nine amino acids. While angiotensin II acts a potent blood vessel constrictor, Ang-1-9 has no effect on blood vessels, but can be converted by ACE to a shorter peptide, Ang-1-7, which is a blood vessel dilator. 4, 5 Three major functions of ACE2 have been described so far. First, ACE2 emerges as a potent negative regulator of the RAS, counterbalancing the multiple functions of ACE. By targeting angiotensin II, ACE2 exhibits a protective role in the cardiovascular system and many other organs. 6 Second, ACE2 has been identified as an essential receptor for the severe acute respiratory syndrome (SARS) coronavirus, which causes severe acute lung failure. Downregulation of ACE2 strongly contributes to the pathogenesis of severe lung failure. Third, both ACE2 and its homologue collectrin can associate with amino acid transporters and play an essential role in the absorption of amino acids in the kidney and gut. 7, 8 As the catalytic efficiency of ACE2 is approximately 400 times higher with angiotensin II as a substrate than with angiotensin I, this axis may possibly be acting as a counterregulatory system against the ACE/Ang II/AT-(1) receptor axis. By means of modulation of ACE2 and Ang-(1-7) in RAS, this axis may be considered an important target for the therapy of cardiovascular and metabolic disorders. 9 ACE2 contains 805 amino acids that share an approximately 40% identity with the N-and C-terminal domains of somatic ACE. 3 With the help of quantitative reverse transcription-polymerase chain reaction (RT-PCR), 3, 10 it has been reported that ACE2 is expressed in a total of 72 human tissues and cells examined, apart from red blood cells. The highest expression was detected in testis, renal and cardiovascular tissues and in all portions of the gastrointestinal tract. The central nervous system and lymphoid tissues expressed relatively low ACE2 levels. 3, 10 Three major groups of parameters influencing the stiffness of the aorta and the large arteries have been described to date: first, physiological properties such as age, gender, body height, pressure, hormonal state and genetic factors; second, environmental factors such as nutrition, smoking, sports performance and aerobic capacity; third, diseases such as hypertension, hypercholesterolaemia, diabetes, coronary heart disease, cerebrovascular disease, renal failure, Marfan syndrome and growth hormone deficiency. 11 The increase in aortic pressure from diastolic to systolic values is determined by the compliance of the aorta as well as the ventricular stroke volume. A high central pulse pressure (PP) is considered to be a marker of increased artery stiffness and represents a well-established independent predictor of cardiovascular morbidity and mortality [12] [13] [14] in hypertensive individuals and even in those considered as having normal blood pressure. 15 PP significantly predicts major adverse cardiovascular events (MACEs), including unstable angina pectoris, myocardial infarction (MI), coronary revascularization, stroke, or death MACEs. 16 An independent correlation between aortic PP and coronary artery disease (CAD) was established in men only, along with age and hypercholesterolaemia. 17, 18 The late decrease in diastolic blood pressure (DBP) after the age of 60, associated with a continual rise in systolic blood pressure (SBP), is consistent with increased large artery stiffness. Higher SBP, if left untreated, may accelerate large artery stiffness and thus perpetuate a vicious cycle. 19 The objective of this research was to determine whether invasively measured central PP in patients indicated for coronarography (to confirm diagnosis of CAD) is associated with two common polymorphisms in the ACE2 region (rs4646156 and rs4646174), which had been previously associated with blood pressure responses to potassium supplementation 20 as well as with dietary sodium interventions. 21
Methods

Study population
From May 2009 to May 2011, a total of 537 patients were enrolled in a prospective study focusing on the effect of ACE2 gene polymorphisms on aortic PP. The patients were referred to the catheter laboratory (cathlab) of the Cardiology Department of the Faculty Hospital Brno for diagnostic coronary angiography. Patients with acute MI, aortic valve disease (aortic stenosis with a peak to peak gradient > 25 mm Hg, aortic regurgitation greater than grade 1), mitral valve disease or ejection fraction (EF) < 50%, were excluded from the study. A total of 307 patients were evaluated. Informed written consent was obtained from all subjects prior to their participation in the trial. The study protocol complied with the Declaration of Helsinki and was approved by the local Ethics Committee.
Definitions and study protocol
Baseline characteristics (history, current symptoms and risk factors) and medication were established prior to the examination. The presence of diabetes mellitus was defined as fasting blood glucose of ≥ 7 mmol/l or the usage of an antidiabetic drug or insulin. Hypercholesterolaemia was defined as total plasma cholesterol ≥ 5 mmol/l or low-density lipoprotein (LDL) cholesterol ≥ 2.6 mmol/l or an existing lipid-lowering drug prescription. Ischaemic heart disease was defined as a ≥ 50% reduction of the intraluminal diameter of any of the coronary arteries (left main, left anterior descending, left circumflex, right coronary) or the main branches with a diameter of ≥ 2.0 mm.
Laboratory methods
Invasive intra-aortic SBP and DBP were measured using a fluid-filled catheter (4Fr pigtail catheter) in the ascending aorta; left ventricle end-diastolic pressure (LVEDP) was measured in the left ventricle with the patient in the supine position. Aortic PP was calculated as the difference between aortic SBP and aortic DBP, mean arterial pressure (MAP) was calculated as follows: (MAP = DBP + (SBP-DBP)/3). The heart rate was recorded using standard electrocardiography monitoring.
Genotyping DNA was extracted from peripheral leukocytes using the standard proteinase K technique. The ACE-2 gene polymorphisms on the X chromosome included in the present study, i.e. rs4646156 (position: c.1071-605 T > A) and rs4646174 (position: c.1896 + 147 G > C) are both located in the intron regions.
The genotyping of both single-nucleotide polymorphisms (SNPs) was carried out using 5′exonuclease (Taqman®) chemistry on the ABI Prism® 7000 system (Applied Biosystems, Foster City, CA, USA). Both assays were validated by double genotyping of 10% of the samples and by direct sequencing using Big Dye v 1.1 terminator chemistry (Applied Biosystems).
Data analysis and statistics
Data were reported as median, range for continuous variables and percentage proportion for discrete variables. In order to test differences between groups, t tests and analysis of variance (ANOVA) tests were used for continuous normally distributed variables and the Mann-Whitney U test and Kruskall-Wallis ANOVA tests for continuous non-normally distributed variables. Pearson's correlation coefficient was used to determinate relations between variables. Univariate and multivariate linear regression was used for adjusting PP values influencing patients' characteristics, comorbidities and medication. A preselection of variables based on univariate linear regression and expert opinion followed by a backward stepwise algorithm were used for the definition of multivariate models.
In silico analysis of possible binding site for transcription factors was performed using the TRANSFAC MATRIX 
Results
The clinical characteristics of the groups according to gender are listed in Tables 1 and 2 .
The main goal of the study was to test the association of X-linked ACE2 gene polymorphisms with central PP. These associations were found to be highly significant when all five possible genotypes in the population had been compared ( Table 3) . The values of PP were higher in women; significant differences among five genotypes in the population were distinguishable.
However, in X-linked polymorphisms, it is generally difficult to distinguish differences associated with gender as opposed to those associated with X-linked polymorphisms independently. Therefore, in a further analysis, patients were evaluated separately according to gender and tested for possible intra-group associations.
Following a sub-division of the patients, no significant associations between the two examined ACE2 polymorphisms and the central PP were observed (p = 0.291 for rs4646156 and p = 0.568 for rs4646174 in men and p = 0.838 for rs4646156 and p = 0.785 for rs4646174 in women). A significant association with body height was found in the case of both polymorphisms (p = 0.01 for rs4646156 and p = 0.02 for rs4646174, Tables 3 and 4) in men, but not in women. When comparing men and women, a highly significant difference in height and weight (but not in body mass index (BMI)) was observed ( Table 1) .
In women, significant differences in age were observed (p = 0.05, the CC genotype of rs4646174 polymorphism was younger -58 years compared to 63 of GG and GC carriers) as well as differences in blood creatinine level (the CC genotype of the rs4646174 polymorphism has the lowest levels of all genotypes; p = 0.05; Table 4 ). A highly significant difference in creatinine levels between men and women was also established (Table 1) . In terms of clinical aspects, a significant difference among carriers of rs4646156 genotypes was found: The AA genotype had a 7.81x higher risk of AP_CCS 3 in women (odds ratio (OR) = 7.81, 95% confidence interval (CI) 1.38-44.24, Pcorr = 0.05, sensitivity 0.288, specificity 0.961, power test (PT) 0.700). A significant difference in allelic frequency of ACE2 rs4646174 was found between women with and without significant stenosis of the circumflex branch of the left coronary artery. In men, there was a higher incidence of MI in G0 genotype carriers of rs54646174 (OR ratio = 7; 95% CI 0.86-56.73, p = 0.005, sensitivity 1.00, specificity 0.33, PT 0.80, Table 4 ). No similar association was observed in women.
In women, a pharmacogenetic aspect was observed: The patients with the GG and GT genotypes of the ACE24646174 polymorphism were significantly more often treated by beta blockers compared to the CC carriers (OR = 4.77, 95% CI 1.25-18.20, Pcorr = 0.041, sensitivity 0.961, specificity 0.164, PT 0.80).
Finally, we attempted testing ACE2 genotypes as possible independent predictors of central PP using multivariate analysis. The most suitable model included brachial PP, age, ACE2 4646174 genotypes and the number of affected arteries ( Table 5 ).
Discussion
No similar study of ACE2 gene variability and invasively measured central PP has been found in the literature that could be used for comparison with our population. ACE2 SNPs (including rs4646156) displayed no association with blood pressure or (brachial) PP in a multivariate model corrected for age and BMI as covariates in another study. 23 However, some genetic variants in the ACE2 gene have been associated with left ventricular mass, septal wall thickness and left ventricular hypertrophy in men. 23 In Caucasians with type 2 diabetes, genetic variation in ACE2 has been associated with hypertension and reduced systolic function in men, and with hypertension and increased LV mass in women. 24 A significant association with body height was found in cases of both polymorphisms in men, but not in women in our study. Body height was reported to be a determinant of timing and magnitude of reflected arterial pulses. 25 The influence of body height on the risk of coronary artery diseases is mediated by many different mechanisms: e.g. by stiffening of the aorta in late systole and by reducing aortic diastolic pressure and duration. 25 In our study, significant differences among the rs4646174 polymorphism genotypes in age as well as in blood creatinine level were observed in women. Independently of coronary atherosclerosis, aortic PP integrates the predictive value of aortic, inflammatory and renal factors. 26 Increased plasma creatinine and aortic pulse wave velocity were found to be independently and positively correlated. 26 ACE2 might also play an important role in maintaining a balanced status of the local RAS synergistically with ACE by counter-regulatory effects confounded by the presence of hypertension. Thus, ACE2 may exert pivotal effects on cardiovascular and renal conditions. 27 In our study, women with the GG and GT genotypes of the ACE24646174 polymorphism were significantly more prone to have been treated by beta blockers compared to the CC carriers. No significant changes between ACE24646174 hemigenotypes in beta blocker treatment in men were observed. The older hypertensive subjects who used diuretics alone or in combination with beta blockers were found to have lower mean PP in comparison with those using beta blockers alone. 28 Most of the protocols used to de-stiffen large arteries required the administration of a renin-angiotensin-aldosterone system inhibitor, which was frequently associated with the use of a diuretic and/or a calcium antagonist, but not with a classic beta blocker. These protocols were evaluated in randomised controlled trials and showed significant reduction in cardiovascular risk, particularly in comparison with beta blockers. 29 Based on our results, in women, a higher risk of some rs4646156 genotypes of ACE2 polymorphism for severe angina pectoris was observed. Another ACE2 polymorphism (rs2285666) was associated with the risk of cardiovascular death in women. 30 On the other side, no man in our study with C genotype in rs4646174 had a positive history of MI. ACE2 exerts cardioprotective effects by preserving jeopardised cardiomyocytes in the border ischaemic zone following experimental MI in rats. The reduction in hypertrophy and fibrosis with a selective ACE2 inhibitor C16 suggests that ACE2 activity has effects on post-MI remodelling. 6 The aortic PP was significantly and independently correlated with angiographically determined coronary artery stenosis in another study 31 in agreement with our model, which includes ACE2 polymorphism rs4646174, as the multivariate regression modelling revealed a significant association of rs4646174 as well as a number of affected arteries with the PP in our study. The mechanism through which ACE2 intronic polymorphisms could exert a functional effect on PP is elusive. In the in silico analyses, no binding site for transcription factors were found in the region of these two polymorphisms. ACE2 gene and protein expression and enzymatic activity are developmentally regulated in a tissue-specific manner 32 in animal experiments. Relatively high ACE2 protein levels and enzymatic activity observed during gestation in mouse models may play a role in kidney, lung, brain and heart organogenesis. 32 ACE2 gene deletion in ACE2-knockout mice has been shown to promote age-dependent oxidative stress, autonomic dysfunction and hypertension, while targeted ACE2 gene therapy decreases reactive oxygen species (ROS) formation via β-nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibition and improves autonomic function in these animals. 33 In a model of foetal programmed hypertension, the nuclear ROS responses to AT II was found to be enhanced while both AT2 and AT7 stimulation of nitric oxide are decreased, suggesting an imbalance in the intracellular RAS may contribute to the development of programming future cardiovascular events. 34 In conclusion, numerous significant associations were observed in our study, both in males and females, with respect to PP and distribution of genotypes of investigated polymorphisms in the ACE2 region, which seem to reflect, at least partially, the different pathophysiological basis for clinical indication of coronarography in men and women. More research into the role of ACE2 genetic variability in PP regulations is necessary to help develop more detailed physiological and pathophysiological comprehension of PP regulation. This is a pilot study presenting the data from a cross-sectional investigation; however, further studies in prospective design on large population samples of different ethnicity are imperative.
